US EditionBelite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares - Belite Bio (NASDAQ:BLTE)
Belite Bio aims to raise approximately $350 million to fund commercialization efforts and expand its drug development pipeline, including building its sales network and manufacturing capabilities.
5 Articles
5 Articles
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares - Belite Bio (NASDAQ:BLTE)
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each representing one of its ordinary shares. All of the securitie…
Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results
Belite Bio (NASDAQ:BLTE – Get Free Report) released its quarterly earnings data on Monday. The company reported $0.95 earnings per share (EPS) for the quarter, FiscalAI reports. Belite Bio Stock Up 12.1% BLTE traded up $16.58 during trading on Monday, reaching $154.02. 753,061 shares of the stock traded hands, compared to its average volume of […]
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
